Disclaimer

The system provides an estimate of in vivo efficacy of commonly used antiretroviral drug combinations based on user-defined information of HIV genotype (mandatory) and additional patient information (recommended). The engine is not intended as a replacement for standard of care but can be used by HIV specialists as an additional treatment decision support tool. Although analysis of a large data set of medical records has shown a good performance of the system, there is no warranty that its use will improve patient health. HIV care must rely on a solid knowledge of the complex host-virus interaction and proper consideration of patient status and commitment.

Database

The EuResist Integrated DataBase (EIDB) was set up to develop the EuResist prediction system. The EIDB is currently one of the largest data sets suitable for training genotype-centered treatment response models.

The EIDB is open for scientific studies under approval of the Scientific Board and following the Authorship Policy.

The EIDB includes information about patients, drug therapies, AIDS defining events, CD4 and viral load measurements and HIV genomic sequences. As of June 2017 it contains the following data:

Patients 81.227
CD4 counts 1.126.492
ENV 196
GP120 sequences 3.952
GP41 sequences 1.389
IN sequences 8.165
PR sequences 79.809
RT sequences 80.367
Therapies 172.140
V3 sequences 1.071
Viral Load data 1.118.249

The EIDB integrates biomedical information from the three founding national databases: the ARCA database (Italy), the AREVIR database (Germany), and data from Karolinska Institute (Sweden). The original data set is continuously updated with new data in order to improve the accuracy of the prediction system.

Following the EIDB setup, other centers’ data have also been uploaded:

Instituto de Higiene e Medicina Tropical (Portugal); irsiCaixa Foundation (Spain); the Rega Institute (Belgium); Laboratoire de Rétrovirologie of CRP-Santé (Luxembourg), data from the DUET study conducted by Tibotec, the National Referral Laboratory of Rwanda, Ivanovsky Institute of virology, Russia, Boheringer Ingelheim.

2017 update
ARCA patients 37058
  therapies 96756
  viral loads 576562
  CD4 counts 624855
  ENV 9
  gp120 3923
  gp41 1240
  IN 3533
  PR 37900
  RT 38254
  V3 0
AREVIR patients 15738
  therapies 0
  viral loads 189704
  CD4 counts 171074
  ENV 0
  gp120 29
  gp41 103
  IN 2823
  PR 12288
  RT 12318
  V3 730
LISBON patients 11462
  therapies 12260
  viral loads 48285
  CD4 counts 15350
  ENV 0
  gp120 0
  gp41 0
  IN 410
  PR 14181
  RT 14181
  V3 0
KAROLINSKA patients 10858
  therapies 46190
  viral loads 241889
  CD4 counts 248047
  ENV 187
  gp120 0
  gp41 0
  IN 345
  PR 8578
  RT 8776
  V3 0
BI patients 1361
  therapies 1590
  viral loads 11192
  CD4 counts 0
  ENV 0
  gp120 0
  gp41 0
  IN 0
  PR 0
  RT 0
  V3 0
VIROLAB_LEUVEN patients 1246
  therapies 3822
  viral loads 14765
  CD4 counts 30736
  ENV 0
  gp120 0
  gp41 0
  IN 234
  PR 1484
  RT 1449
  V3 0
VIROLAB_IRSICAIXA patients 1003
  therapies 6584
  viral loads 13755
  CD4 counts 13488
  ENV 0
  gp120 0
  gp41 0
  IN 0
  PR 1383
  RT 1383
  V3 0
LUXEMBOURG patients 992
  therapies 4073
  viral loads 21610
  CD4 counts 20855
  ENV 0
  gp120 0
  gp41 46
  IN 817
  PR 2742
  RT 2742
  V3 341
Karasi-Rwanda patients 865
  therapies 665
  viral loads 487
  CD4 counts 488
  ENV 0
  gp120 0
  gp41 0
  IN 0
  PR 617
  RT 630
  V3 0
RUSSIA patients 444
  therapies 0
  viral loads 0
  CD4 counts 0
  ENV 0
  gp120 0
  gp41 0
  IN 3
  PR 436
  RT 434
  V3 0
TIBOTEC patients 200
  therapies 200
  viral loads 0
  CD4 counts 1599
  ENV 0
  gp120 0
  gp41 0
  IN 0
  PR 200
  RT 200
  V3 0

How to contribute to the data base

You can contribute your data to the EuResist initiative and have the possibility to query the whole data set for study proposals (upon request). In order to facilitate the entry of additional data providers, general rules for participation have been agreed upon as follows.

  1. Data provided by external contributors are provided solely for development of the treatment response models (i.e. the focus of the EuResist project); any other use is subject to information to and explicit approval by the contributing center;
  2. The task of integrating new data into the EIDB will be carried out by EuResist with the collaboration of the data provider, limited to providing information on database platform and schema and sending data via the method agreed upon. Integrating data ensures a quality control made by the EIDB administrator at the advantage of the contributing center;
  3. The co-authorship policy reserves one slot for each data provider in each scientific paper and congress presentation provided this is in-line with the journal editorial policy in terms of limitation in the number of authors or kind of work performed;
  4. Data contributed remain the property of the contributing center for ever. The data provider reserves the right to have its data permanently removed from EIDB at any moment without any need to justify this decision. Should this occur, the data are considered available only for pending papers explicitly agreed upon, i.e. being submitted for publication;
  5. Should EuResist end, each external dataset will be removed from the EIDB unless the contributing center explicitly requests that the data remain in the EIDB